New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;STRA;JNJ;IQNT;HES;VNO;NKTR;JCP;CAT;PBR;VRTX;KRC;GRMN From The Last 14 Days
Check below for free stories on BMY;STRA;JNJ;IQNT;HES;VNO;NKTR;JCP;CAT;PBR;VRTX;KRC;GRMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 15, 2014
07:49 EDTJNJJohnson & Johnson reports Q2 Worldwide Pharmaceutical sales of $8.5B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson raises FY14 EPS to $5.85-$5.92 from $5.75-$5.85
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales up 14.9% to $9.13B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 EPS excluding items $1.66, consensus $1.55
Subscribe for More Information
07:35 EDTBMYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
11:49 EDTPBRStocks with call strike movement; TSLA PBR
Tesla (TSLA) January 270 call option implied volatility increased 2% to 44, Petrobras (PBR) November 18 call option implied volatility increased 3% to 44 according to IVolatility.
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
07:43 EDTCATGE far ahead of Caterpillar in race for cleaner diesel train, WSJ says
Caterpillar (CAT) has fallen far behind in the race to offer a locomotive that meets stricter emission standards taking effect next year, with its Electro-Motive Diesel unit stating that its freight trains probably won't be available until 2017, while General Electric (GE) is already testing trains that comply with the new rules, reported The Wall Street Journal. Reference Link
05:49 EDTPBRPetrobras added to LatAm Spotlight List at Goldman
Subscribe for More Information
July 13, 2014
15:18 EDTJCPJ.C. Penney CEO successor search faces setback, WSJ says
It appears that J.C. Penney (JCP) is not having an easy time of identifying a successor for current CEO Myron Ullman, says the Wall Street Journal. According to the WSJ report, Mindy Grossman, CEO of HSN (HSNI), who is considered the lead candidate for Ullman's position, had been in talks with J.C. Penney but could not agree on terms and negotiations broke down moths ago. Reference Link
July 11, 2014
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
July 10, 2014
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. “We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our company’s commitment to deliver innovative treatment options for patients with cancer,” said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.
08:10 EDTHESMorgan Stanley's Vintage Values 2015 list selected
Subscribe for More Information
08:02 EDTVRTXVertex announces retirement of Chief Scientific Officer Mueller
Subscribe for More Information
06:28 EDTVNOOptions expected to be active
Options expected to be active: LL PBPB VNO FDO WFC COST ZUMZ UAL BA
06:19 EDTGRMNGarmin price target raised to $70 from $65 at Citigroup
Citigroup raised its price target for Garmin shares to $70 saying the company's fitness band vívofit is well positioned to benefit from the faster than expected growth in the activity monitor category. Citi believes 2M-2.5M activity monitors were shipped in Q1, and it expects strong momentum through 2014 and 2015. It reiterates a Buy rating on Garmin.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use